Patent ID: 8481038
Filing Date: 2013-07-09
Classification: A61K,A61P,C07K

Abstract:
1. A method of treating a human having a cancer, the method comprising: reducing the fibroblast growth factor-2 (FGF-2) plasma concentration of the human below 4 pg/ml for at least one week by administering to the human a soluble Fibroblast Growth Factor Receptor 1 (FGFR1) fusion protein at a dose of at least about 2 mg/kg body weight, wherein the soluble FGFR1 fusion protein comprises an FGFR1 extracellular domain linked to a Fc polypeptide, the human has an FGF-2 plasma concentration of at least 6 pg/ml prior to administration of the soluble FGFR1 fusion protein, and the FGF-2 plasma concentration is determined according to an electrochemiluminescence assay, which utilizes an anti-FGF-2 antibody as the primary antibody and a ruthenium metal chelate anti-human growth factor antibody blend as the secondary antibody.